These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36655340)

  • 1. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
    Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
    Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
    Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
    J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
    Zhang X; McAdam Marx C
    J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
    Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
    Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
    Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
    Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
    Mody RR; Meyer KL; Ward JM; O'Day KB
    Diabetes Ther; 2023 Dec; 14(12):2045-2055. PubMed ID: 37770706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
    Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H
    Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
    Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
    Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
    BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
    Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
    Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
    Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
    Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
    Osumili B; Fan L; Paik JS; Pantalone KM; Ranta K; Sapin H; Tofé S
    Diabetes Res Clin Pract; 2024 Jun; 212():111717. PubMed ID: 38777128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 19. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
    Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
    Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.